Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$460.72 USD

460.72
1,689,919

+5.98 (1.32%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $460.90 +0.18 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Zacks Equity Research

Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.

Zacks Equity Research

Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates

by Zacks Equity Research

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.

Zacks Equity Research

National Vision (EYE) Q3 Earnings Top Estimates, Margins Up

by Zacks Equity Research

National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.

Zacks Equity Research

Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.

Zacks Equity Research

Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

Zacks Equity Research

Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.

Zacks Equity Research

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Zacks Equity Research

CVS Health (CVS) Q3 Earnings Top Estimates, 2020 View Up

by Zacks Equity Research

CVS Health's (CVS) Q3 pharmacy claims processed rise attributable to strong net new business, partially offset by reduced new therapy prescriptions.

Zacks Equity Research

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.

Zacks Equity Research

Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.

Zacks Equity Research

LHC Group (LHCG) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

LHC Group's (LHCG) third-quarter results benefit from organic growth in home health as well hospice admissions.

Zacks Equity Research

Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates

by Zacks Equity Research

Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.

Zacks Equity Research

Inogen (INGN) Stock Loses 9.2% After Delivering Loss in Q3

by Zacks Equity Research

Inogen (INGN) saw revenue decline within its Sales segment in Q3

Zacks Equity Research

PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat

by Zacks Equity Research

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.

Zacks Equity Research

Becton Dickinson (BDX) Earnings Surpass Estimates in Q4

by Zacks Equity Research

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in the fiscal fourth quarter.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) rides high on the launch of the Axeos imaging system in the third quarter.

Zacks Equity Research

Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.

Zacks Equity Research

Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up

by Zacks Equity Research

Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume

Zacks Equity Research

Fresenius Medical (FMS) Stock Gains 5.6% on Q3 Earnings Beat

by Zacks Equity Research

Fresenius Medical's (FMS) third-quarter earnings benefit from stable segmental performance.

Zacks Equity Research

Change Healthcare (CHNG) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal second-quarter results benefit from solid performance in the Network Solutions segment.

Zacks Equity Research

Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results reflect strong segmental performance.

Zacks Equity Research

AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.

Zacks Equity Research

Surmodics (SRDX) Reports Q4 Loss, Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.

Zacks Equity Research

Hologic (HOLX) Q4 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Hologic (HOLX) exhibited robust segmental growth in fourth-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Zacks Equity Research

Thermo Fisher (TMO) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.